This focus could potentially offer a more effective and safer treatment for Alzheimer’s, addressing ... Alzheimer’s disease. The company’s lead drug candidate, ACU193, is a subclass monoclonal ...

An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

In the early phase of Alzheimer’s disease, astrocytes are the primary source of APOE in the brain. This study examined the ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

A recent study from RUSH University in Chicago suggests that eating diets rich in green leafy vegetables, along with foods ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system. Microglia, the primary immune cells of the central ...

In healthy brains, immune cells called microglia patrol for damage, clearing away debris and harmful proteins. But in the presence of the APOE4 protein-;the most important genetic risk factor for ...

The following is a summary of “Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From ...